• Moesin as a Biomarker of Endothelial Injury in Sepsis: Key I

  2026-06-04

  The reference study identifies moesin as a novel and quantifiable biomarker for endothelial injury severity in sepsis, establishing mechanistic links between moesin expression, vascular permeability, and inflammatory signaling. These findings offer researchers a compelling target for both diagnostic and mechanistic exploration in sepsis models.

• ERAD-Hijacking Chimeras Enable Targeted TM Protein Degradati

  2026-06-03

  Song et al. have developed small-molecule ERAD-engaging chimeras (ERADECs) that selectively degrade transmembrane (TM) proteins by hijacking the ER-associated degradation pathway. This work overcomes persistent barriers in targeted protein degradation, broadening the experimental toolkit for membrane protein research and immunology.

• Cannabis Terpenes Relieve Neuropathic Pain via A2A Receptor

  2026-06-03

  This study demonstrates that select terpenes from Cannabis sativa induce antinociception in mouse models of chronic neuropathic pain through adenosine A2A receptor activation, not cannabinoid pathways. The findings highlight terpenes as promising, non-rewarding pain therapeutics and provide a mechanistic basis for their analgesic action.

• Staurosporine: Broad-Spectrum Kinase Inhibitor for Cancer Re

  2026-06-02

  Staurosporine remains the gold-standard broad-spectrum serine/threonine protein kinase inhibitor for dissecting kinase signaling and inducing apoptosis in cancer cell lines. This article delivers actionable workflow enhancements, troubleshooting guidance, and new assay paradigms inspired by breast cancer microenvironment breakthroughs.

• Oridonin Blocks TAA-Induced Osteoclastogenesis via MAPK/NF-κ

  2026-06-02

  This study demonstrates that oridonin attenuates thioacetamide (TAA)-induced bone loss by inhibiting osteoclastogenesis through suppression of the MAPK/NF-κB signaling pathway and promotes osteogenesis via BMP-2/RUNX2. The dual-action mechanism provides a foundation for new therapeutic strategies in osteoporosis, highlighting an integrative approach to inflammation and bone metabolism.

• Ibuprofen Toxicology and Biodegradation: Key Findings for Re

  2026-06-01

  Jan-Roblero and Cruz-Maya's 2023 review provides a comprehensive analysis of ibuprofen as an emerging environmental contaminant, highlighting its toxicological impacts, persistence, and biodegradation challenges. The findings inform both environmental monitoring and experimental study design for researchers investigating NSAID fate, inflammation pathways, or pain mechanisms.

• Quinolone-Coumarin Hybrids and Novobiocin: New Tools Against

  2026-06-01

  This study evaluates novel quinolone–coumarin hybrid molecules, synthesized from fluoroquinolones and Novobiocin, for their selective in vitro anti-parasitic activity against Toxoplasma gondii. The findings highlight specific hybrids and Novobiocin as promising leads, showing superior selectivity and efficacy compared to standard therapies, with implications for antiparasitic drug development and DNA-targeting research.

• Phenacetin in Applied Pharmacokinetic Research: Optimizing W

  2026-05-31

  Phenacetin (N-(4-ethoxyphenyl)acetamide) serves as a high-purity model compound for advanced pharmacokinetic assays, especially in hiPSC-derived intestinal organoids. This article details robust experimental protocols, troubleshooting strategies, and practical insights that leverage APExBIO’s research-grade Phenacetin for reproducible and insightful scientific research.

• Lignans from Rosemary Roots: Novel Anti-inflammatory Compoun

  2026-05-30

  This study systematically investigates the roots of Rosmarinus officinalis, isolating eight lignans and four phenylpropanoids, including three previously unreported compounds. The findings highlight specific lignans with potent, dose-dependent anti-inflammatory activity, offering new leads for inflammation research and natural product pharmacology.

• PPM-18: Precision iNOS Inhibition for Sepsis & Inflammation

  2026-05-29

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) delivers benchmark selectivity for inducible nitric oxide synthase (iNOS) inhibition via targeted NF-κB pathway modulation, advancing workflows in sepsis and immune response studies. With robust in vitro and in vivo validation, PPM-18 offers reproducible performance and troubleshooting advantages for translational inflammation research.

• Mifepristone (RU486): Shaping Translational Research Frontie

  2026-05-29

  Explore how Mifepristone (RU486) is driving new paradigms in cancer and reproductive biology research. This thought-leadership article blends mechanistic insights with actionable strategies for translational researchers, contextualizing robust evidence and workflow mastery with a forward-looking perspective.

• FKBP9 Drives Glioblastoma Malignancy and ER Stress Resistanc

  2026-05-28

  Xu et al. (2020) uncover that FKBP9 promotes glioblastoma growth and confers resistance to endoplasmic reticulum (ER) stress inducers by modulating the IRE1α-XBP1 pathway. This study highlights FKBP9 as a critical mediator of glioblastoma malignancy, suggesting new avenues for targeting ER stress responses in high-grade glioma.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-05-28

  Explore how 5-(N,N-dimethyl)-Amiloride hydrochloride advances endothelial injury and sepsis research through precise Na+/H+ exchanger inhibition. This article offers a uniquely deep analysis of its relevance for translational models and intracellular pH regulation.

• Solving Cell Assay Challenges with Methylprednisolone Sodium

  2026-05-27

  This article delivers actionable, scenario-driven guidance for biomedical researchers and lab technicians leveraging Methylprednisolone Sodium Succinate (SKU B4953) in cell viability, proliferation, and cytotoxicity assays. We address real-world workflow challenges, provide protocol optimization strategies, and explain how APExBIO’s high-purity product enables reproducible, quantitative results in inflammation and immunology studies.

• Bafilomycin A1: V-ATPase Inhibitor for Lysosomal Function Re

  2026-05-27

  Bafilomycin A1 stands out as a benchmark V-ATPase inhibitor for dissecting lysosomal function, intracellular pH regulation, and mitophagy. Leveraging recent mechanistic studies, this guide offers actionable protocols, troubleshooting insights, and advanced workflow enhancements for maximizing reproducibility in cell biology and disease modeling.

552 records 16/37 page Previous Next First page 上5页 1617181920 下5页 Last page